Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.18M Sell
184,580
-12,534
-6% -$334K 0.18% 116
2025
Q4
$4.91M Buy
197,114
+32,990
+20% +$832K 0.17% 121
2025
Q3
$4.18M Buy
164,124
+70,781
+76% +$1.75M 0.15% 137
2025
Q2
$2.26M Sell
93,343
-9,007
-9% -$210K 0.09% 205
2025
Q1
$2.59M Buy
102,350
+32,713
+47% +$856K 0.11% 193
2024
Q4
$1.85M Buy
69,637
+6,925
+11% +$188K 0.14% 180
2024
Q3
$1.81M Buy
62,712
+11,867
+23% +$346K 0.14% 194
2024
Q2
$1.42M Buy
50,845
+9,565
+23% +$263K 0.12% 222
2024
Q1
$1.15M Sell
41,280
-1,260
-3% -$35K 0.1% 262
2023
Q4
$1.18M Sell
42,540
-8,010
-16% -$242K 0.11% 230
2023
Q3
$1.5M Sell
50,550
-17,786
-26% -$629K 0.17% 176
2023
Q2
$2.44M Sell
68,336
-3,305
-5% -$129K 0.27% 101
2023
Q1
$2.92M Sell
71,641
-26,358
-27% -$1.14M 0.31% 80
2022
Q4
$5.02M Sell
97,999
-206
-0.2% -$9.88K 0.59% 29
2022
Q3
$4.57M Buy
98,205
+4,131
+4% +$201K 0.56% 37
2022
Q2
$4.75M Buy
94,074
+582
+0.6% +$29.7K 0.57% 33
2022
Q1
$4.84M Sell
93,492
-221
-0.2% -$11.5K 0.56% 33
2021
Q4
$4.95M Buy
+93,713
New +$4.64M 0.63% 25

Other funds holding PFE

Ascent Group's PFE Position: Q1 2026 in Review

Ascent Group reduced its Pfizer (PFE) stake by 6.4% in Q1 2026, selling an estimated $334K and leaving 184,580 shares worth $5.18M. The position accounts for 0.18% of the portfolio, ranked #116.

Ascent Group first reported a position in PFE in Q4 2021 and has held it in 18 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Ascent Group held 184,580 shares of Pfizer worth $5.18M as of Q1 2026.
  • Ascent Group sold 12,534 Pfizer shares in Q1 2026, an estimated $334K.
  • Pfizer made up 0.18% of Ascent Group's portfolio in Q1 2026, its #116 holding.
  • Ascent Group first reported a position in Pfizer in Q4 2021 and has held it in 18 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.